RESEARCH
Veracity Clinical Research contributes to global knowledge
Veracity Clinical Research is fortunate to contribute to world literature in the field of dermatology. Below is a list of research papers, conference posters, abstracts and oral presentations that our principle investigator, Dr Lynda Spelman, and sub-investigators have authored or contributed to for over 25 years.
Publications:
2024
Lebwohl, M., Warren, R. B., Sofen, H., Imafuku, S., Paul, C., Szepietowski, J. C., Spelman, L., Passeron, T., Vritzali, E., Napoli, A., Kisa, R. M., Buck, A., Banerjee, S., Thaçi, D. & Blauvelt, A. (2024). Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials. British Journal of Dermatology, ljae014. https://doi.org/10.1093/bjd/ljae014
2023
Cox, C., Fry, K., Sivakumaran, Y., Spelman, L. and Khosrotehrani, K. (2023), Anti-IL17A, Ixekizumab, for treatment-resistant chronic venous leg ulcers: A phase II randomized, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol, 37: e973-e975. https://doi.org/10.1111/jdv.19041
Guttman-Yassky, E, Weidinger, S, Simpson, E, Gooderham, M, Irvine, A, Spelman, L, Silverberg, J, Elmaraghy, H, DeLuca-Carter, L, Buziqui Piruzeli, M L, Hu, C, Yang, F E, Pierce, E, Bardolet, L, & Thaci, D (2023). Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 7(6), s271. https://doi.org/10.25251/skin.7.supp.271
Lee R-L, Liyanage U, Fry K, Brown S, von Schuckmann L, Spelman L, et al. Patterns and cost of care according to keratinocyte cancer risk stratification in a volunteer population screening clinic: Real-world data from the TRoPICS study. Australas J Dermatol. 2023; 64: 389–396. https://doi.org/10.1111/ajd.14054
Potter, A., Baker, C., Curran, W. J., Boike, T. P., Spelman, L., Shumack, S., & Foley, P. (2023). Successful management of Australian patients with locally advanced keratinocyte cancer (KC) and/or extensive skin field cancerization (ESFC), using widefield volumetric arc radiation therapy (VMAT): Report with 24-month follow-up. JCO 41, 9586-9586. https://doi.org/10.1200/JCO.2023.41.16_suppl.9586
Spelman L, Potter AE, Baker C, Shumack S, Sinclair R, Christie D, et al. Efficacy and safety analysis: 24-month outcomes from a prospective cohort of 106 fields treated with widefield radiation therapy for extensive skin field cancerization, with or without keratinocyte cancers. JEADV Clin Pract. 2023; 1–11. https://doi.org/10.1002/jvc2.312
Wang, J., White, J., Sansone, K. J., Spelman, L., Sinclair, R., Yang, X., Pan, W., & Wei, Z. (2023). Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clinical and translational science, 16(12), 2614–2627. https://doi.org/10.1111/cts.13656
2022
Baker, C., James, A., Supranowicz, M., Spelman, L., Shumack, S., Cole, J., Weightman, W., Sinclair, R. & Foley, P. (2022). Method of Assessing Skin Cancerization and KeratosesTM (MASCK™): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerization. Clinical and Experimental Dermatology, 47(6), 1144-1153. https://doi.org/10.1111/ced.15136
Darch, K. M., & Spelman, L. J. (2022). The 15-year itch: A case of chronic atopic dermatitis unresponsive to topical corticosteroids. Australian Journal of General Practice, 51(3), 137–138. https://search.informit.org/doi/10.3316/informit.356573503404491
Foley, P., Kerdraon, Y. A., Hogden, J. P., Shumack, S., Spelman, L., Sebaratnam, D. F., Su, C. S., & Katelaris, C. H. (2022). Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting. The Australasian journal of dermatology, 63(4), 421–436. https://doi.org/10.1111/ajd.13924
Foley, P., Spelman, L., Murrell, D. F., Mate, E., Tronnberg, R., & Lowe, P. M. (2022). Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study. The Australasian journal of dermatology, 63(3), 312–320. https://doi.org/10.1111/ajd.13893
Potter, A E, Baker, C, Shumack, S, Sinclair, R, Curran Jr, W J, Christie, D, Wong, B, Foley, P, O’Brien, P, Spelman, L & on behalf of the National Dermatology Radiation Oncology Registry (NDROR) investigators and sites. (2022) Preliminary efficacy and safety analysis: 12-month results in 83 patients using a novel approach of widefield radiation therapy for extensive skin field cancerization with or without keratinocyte cancers, Journal of Dermatological Treatment, 33:5, 2634-2642, https://doi.org/10.1080/09546634.2022.2067814
Spelman, L., Christie, D., Kaminski, A., Baker, C., Supranowicz, M., & Sinclair, R. (2022). Radiotherapy, Utilizing Volumetric Modulated Arc Therapy, for Extensive Skin Field Cancerization: A Retrospective Case Series Assessing Efficacy, Safety, and Cosmetic Outcomes at 12 Months After Treatment. Case Reports in Dermatology, 14(1), 31-38. https://doi.org/10.1159/000521067
Spelman, L., et al. (2022). Baseline Demographics, Comorbidities, And Treatment Patterns In Asian Adults With Atopic Dermatitis Who Received Dupilumab In A Real-World Setting. Intern Med J, 52: 7-8. https://doi.org/10.1111/imj.9_15894
2021
Yamada, M., Miller, D. M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications, 23, 100830. https://doi.org/10.1016/j.conctc.2021.100830
Wu, JJ, Spelman, L, Tan, JL et al. (2021). Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results from the LIBERTY AD CHRONOS Clinical Trial. Published in Dermatology and Therapy, 28 January 2021. https://doi.org/10.1007/s13555-021-00487-y
Sinclair, R, Baker, C, Spelman, L, Supranowicz, M and MacMahon, B (2021). A review of actinic keratosis, skin field cancerisation and the efficacy of topical therapies. Australasian Journal of Dermatology, 62: 119-123. https://doi.org/10.1111/ajd.13447
Yamada M, Miller DM, Lowe M, Rowe C, Wood D, Soyer HP, Byrnes-Blake K, Parrish-Novak J, Ishak L, Olson JM, Brandt G, Griffin P, Spelman L, Prow TW. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications, 2021 Aug 4: 100830. https://doi.org/10.1016/j.conctc.2021.100830
Goodman GJ, Spelman LJ, Lowe N, Bowen B. Randomized, Placebo-Controlled Phase 1/2 Study to Determine the Appropriate ATX-101 Concentration for Reduction of Submental Fat. Dermatologic Surgery 2021 Aug 1; 47(8): 1065-1070. PMID: 34115682 / https://doi.org//10.1097/DSS.0000000000003092
Kong F, Moreira-Lucas TS, Kaminski A, Spelman L. Management of disseminated superficial actinic porokeratosis and intraepidermal squamous cell carcinoma with low-dose radiation therapy. Australian Journal of Dermatology 2021 Aug; 62(3): 410-412. Epub 2021 May 6. PMID: 33954983 / https://doi.org/10.1111/ajd.13605
Lobo Y, Lee RC, Spelman L. Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature. Case Reports in Dermatology 2021 May 4; 13(2): 248-256. PMID: 34177514 / https://doi.org/10.1159/000515246
2020
Wollenberg, A, Blauvelt, A, Guttman-Yassky, E, Worm, M, Lynde, C, Lacour, JP, Spelman, L, Katoh, N, Saeki, H, Poulin, Y, Lesiak, A, Kircik, L, Cho, SH, Herranz, P, Cork, MJ, Peris, K, Steffensen, LA, Bang, B, Kuznetsova, A, Jensen, TN, Østerdal, ML, Simpson, E L and on behalf of the ECZTRA 1 and ECZTRA 2 study investigators. (2020). Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). https://doi.org/10.1111/bjd.19574
Spelman, L., Rubel, D., Brnabic, A., Burkhardt, N., Riedl, E. & Foley, P. (2020). A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis. Published in the Journal of Dermatological Treatment. https://doi.org/10.1080/09546634.2020.1752888
2018
Fogarty, G.B., Christie, D., Spelman, L.J., Supranowicz, M.J., Sinclair, R.J. (2018). Can Modern Radiotherapy be used for Extensive Skin Field Cancerisation: An Update on Current Treatment Options. Published in Biomedical Journal of Scientific and Technical Research. https://doi.org/10.26717/BJSTR.2018.04.000998
Spelman, L. et al. (2018). An Investigator Blinded, Clinical Trial Assessing the Efficacy of Superfine Merino Wool Base Layer Garments (SMWBG) in Children with Atopic Dermatitis (AD) Measuring SCORAD1, EASI2, POEM3 and DSA4 Scores. Biomedical Journal of Scientific & Technical Research. https://doi.org/10.26717/BJSTR.2018.07.001450
2016
Spelman, L., Rubel, D., Murrell, D.F., See, J.-A., Hewitt, D., Foley, P., Salmon, R., Kerob, D., Pascual, T., Shumack, S. & Fernandez-Penas, P. (2016). DL-PDT possible all year in Australia. Australasian Journal of Dermatology, 57: 24-28. https://doi.org/10.1111/ajd.12295
Zane L.T., Chanda S., Jarnagin K., Nelson D.B., Spelman L. & Stein Gold L.F. (2016). Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy VOL. 8, NO. 8. https://doi.org/10.2217/imt-2016-0023
2015
Spelman, L., Su, J. C., Fernandez-Peñas, P., Varigos, G. A., Cooper, A. J., Baker, C. S., Lee, M., Ring, J. M., & Thirunavukkarasu, K. (2015). Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice. Journal of the European Academy of Dermatology and Venereology: JEADV, 29(11), 2184–2191. https://doi.org/10.1111/jdv.13210
2014
Rubel, D.M., Spelman, L., Murrell, D.F., See, J.-A., Hewitt, D., Foley, P., Kerob, D., Kerrouche, N., Wulf, H.C., Shumack, S. (2014). Daylight PDT with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional PDT in actinic keratosis treatment: a randomized controlled trial. The British Journal of Dermatology, 171: 1164-1171. https://doi.org/10.1111/bjd.13138
2013
Rowe, C., Spelman, L., Oziemski, M., Ryan, A., Manoharan, S., Wilson, P., Daubney, M. and Scott, J. (2013). Isotretinoin and mental health in adolescents: Australian consensus. Published in Australasian Journal of Dermatology, 28 November 2013. https://doi.org/10.1111/ajd.12117
2008
Kaufmann, R., Spelman, L., Weightman, W., Reifenberger, J., Szeimies, R.M., Verhaeghe, E., Kerrouche, N., Sorba, V., Villemagne, H. and Rhodes, L.E. (2008). Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. The British journal of dermatology, 158(5), 994–999. https://doi.org/10.1111/j.1365-2133.2008.08488.x
2006
Hofman, T., Cranswick, N., Kuna, P., Boznanski, A., Latos, T., Gold, M., Murrell, D.F., Gebauer, K., Behre, U., Machura, E., Olafsson, J., Szalai, Z. on behalf of the International Tacrolimus Ointment Study Group. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Archives of Disease in Childhood 2006;91:905-910. https://doi.org/10.1136/adc.2006.094276
2005
Vinciullo, C., Elliott, T., Francis, D., Gebauer, K., Spelman, L., Nguyen, R., Weightman, W., Sheridan, A., Reid, C., Czarnecki, D., & Murrell, D. (2005). Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. The British journal of dermatology, 152(4), 765–772. https://doi.org/10.1111/j.1365-2133.2005.06484.x
2004
Thai, K. E., Fergin, P., Freeman, M., Vinciullo, C., Francis, D., Spelman, L., Murrell, D., Anderson, C., Weightman, W., Reid, C., Watson, A., & Foley, P. (2004). A prospective study of the use of cryosurgery for the treatment of actinic keratoses. International Journal of Dermatology, 43(9), 687–692. https://doi.org/10.1111/j.1365-4632.2004.02056.x
Noakes, R. R., & Spelman, L. (2004). Köbnerization in a woman with generalized lichen sclerosus. The Australasian Journal of Dermatology, 45(2), 144–145. https://doi.org/10.1111/j.1440-0960.2004.00063.x
2003
Martinez-Mir, A., Glaser, B., Chuang, G. S., Horev, L., Waldman, A., Engler, D. E., Gordon, D., Spelman, L. J., Hatzibougias, I., Green, J., Christiano, A. M., & Zlotogorski, A. (2003). Germline fumarate hydratase mutations in families with multiple cutaneous and uterine leiomyomata. The Journal of Investigative Dermatology, 121(4), 741–744. https://doi.org/10.1046/j.1523-1747.2003.12499.x
Freeman, M., Vinciullo, C., Francis, D., Spelman, L., Nguyen, R., Fergin, P., Thai, K. E., Murrell, D., Weightman, W., Anderson, C., Reid, C., Watson, A., & Foley, P. (2003). A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. The Journal of Dermatological Treatment, 14(2), 99–106. https://doi.org/10.1080/09546630310012118
2001
Spelman, L., & Dicker, T. (2001). Aquagenic pruritus relieved by tight fitting clothing. The Australasian Journal of Dermatology, 42(2), 146.
Posters/Abstracts/Oral Presentations:
2023
Armstrong, A. W., Lebwohl, M., Warren, R. B., Sofen, H., Imafuku, S., Ohtsuki, M., Spelman, L., Passeron, T., Papp, K. A., Kisa, R. M., Berger, V., Vritzali, E., Hoyt, K., Colombo, M. J., Banerjee, S., Strober, B., Thaçi, D., & Blauvelt, A. (2023). Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, 7(6), s240. https://doi.org/10.25251/skin.7.supp.240
Fernández-Peñas, P., Rubel, D., Spelman, L., Eisman, S., Gebauer, K., Mahar, P. D., Hanna, S., Johannson, E., Chen, S., Behling, M., Dossenbach, M. & Foley, P. (2023). Efficacy of lebrikizumab in moderate-to-severe atopic dermatitis based on Australian reimbursement criteria for severe atopic dermatitis [Poster]. For presentation at EADV in Berlin; October 11-14, 2023.
Gebauer K, Spelman L, Yamauchi P, Bagel J, Nishandar T, Crane M, Kopeloff I, Kothekar M, Yao SL, Sofen H. (2023). Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. 32nd EADV Congress 2023. 2023 Oct 11; E-poster: Abstract N°: 379.
Gooderham, M., Spelman, L., et al. (2023) Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline demographic and disease characteristics in the phase 3 POETYK PSO-1 and PSO-2 trials [Poster]. Presented at the American Academy of Dermatology (AAD) Annual Meeting; March 17–21, 2023; New Orleans, LA
Korman, N. J., Passeron, T., Gordon, K. B., Okubo, Y., Bagel, J., Sofen, H., Warren, R. B., Bhatia, N., Spelman, L., Winthrop, K., Hippeli, L., Kisa, R. M., Banerjee, S., & Thaçi, D. (2023). Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program. SKIN The Journal of Cutaneous Medicine, 7(2), s119. https://doi.org/10.25251/skin.7.supp.119
Lebwohl, M., Warren, R. B., Sofen, H., Imafuku, S., Paul, C., Szepietowski, J. C., Spelman, L., Passeron, T., Colston, E., Hippeli, L., Napoli, A., Kisa, R. M., Banerjee, S., Menter, A., Thaçi, D., & Blauvelt, A. (2023). Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program [Poster]. SKIN The Journal of Cutaneous Medicine, 7(2), s118. https://doi.org/10.25251/skin.7.supp.118
Sofen, H. L ., Gebauer, K., Spelman, L., Yamauchi, P. S., Yao, S., Kothekar, M., Nishandar, T., Kopeloff, I., Crane, M., Gogineni, R. & Bagel, J. (2023). Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results of a multicenter, randomized, double-blind, placebo-controlled clinical study. [Abstract]
Strober, B., Sofen, H., Imafuku, S., Paul, C., Gooderham, M., Spelman, L., Seo, S. J., Passeron, T., Kisa, R. M., Berger, V., Vritzali, E., Hoyt, K., Colombo, M. J., Banerjee, S., Augustin, M., Stein Gold, L., Alexis, A., Thaçi, D., Blauvelt, A., & Lebwohl, M. (2023). Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, 7(6), s241. https://doi.org/10.25251/skin.7.supp.241
Zouboulis, C., Kirby, J., Tzellos, T., Khattri, S., Alavi, A., Podda, M., Del Marmol, V., Spelman, L., Rolleri, R., Joshi, P., Davis, L., Pansar, I. & Frew, J. (2023). IHS4 outcomes with bimekizumab in patients with moderate to severe hidradenitis suppurativa: Pooled results from the BE HEARD I and II phase 3 trials. Abstract N°: 3512 32ND EADV Congress 2023 11 OCTOBER - 14 OCTOBER 2023.
2022
Armstrong, A. W., Warren, R. B., Sofen, H., Spelman, L., Leonardi, C., Banerjee, S., Wang, T., Throup, J., Colston, E., Napoli, A. & Kimball, A. B. (2022). 34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials. Journal of the American Academy of Dermatology, 87(3), AB156. https://doi.org/10.1016/j.jaad.2022.06.657
Armstrong, A., McBride, S., Spelman, L., Fernández-Peñas, P., Rich, P., Martin, G., ... & Hellot, S. (2022). 33259 Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2) [Poster]. Journal of the American Academy of Dermatology, 87(3), AB175.
Costanzo, A., Spelman, L., Ball, S., Cirri, L., Sun, L., Mert, C., & Silverberg, J. I. (2022, September). From clinical trial to clinical practice: open-label therapy with baricitinib 2 mg in patients with moderate-to-severe atopic dermatitis [Poster]. In BRITISH JOURNAL OF DERMATOLOGY (Vol. 187, No. 3, pp. E82-E83).
Korman, N. J., Passeron, T., Gordon, K. B., Okubo, Y., Bagel, J., Sofen, H., Warren, R. B., Bhatia, N., Spelman, L., Winthrop, K., Hippeli, L., Kisa, R. M., Banerjee, S., & Thaçi D. (2022). Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program [Poster]. Presented at the 31st EADV Congress; 7−10 September 2022; Milan, Italy.
Prajapati, V. H., Glick, B., Spelman, L., Nart, I. F., Calimlim, B., Ladizinski, B., ... & Ehst, B. (2022). 308 Incremental improvements after switching from dupilumab (DUPI) to upadacitinib (UPA) in the Heads Up open-label extension (OLE) study [Poster]. Journal of Investigative Dermatology, 142(8), S53.
Spelman, L., Foley, P., Baker, C., Tilt, N., Lanzafame, A., McDougall, T., & Penas, P. F. (2022, May). Certolizumab pegol for treatment of plaque psoriasis: pooled efficacy outcomes across baseline Psoriasis Area and Severity Index subgroups (CIMPASI-1 and CIMPASI-2) [Poster]. In AUSTRALASIAN JOURNAL OF DERMATOLOGY (Vol. 63, pp. 12-13).
Warren, R. B., et al. (2022). AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. https://doi.org/10.1136/annrheumdis-2022-eular.1377
Warren, R. B., Sofen, H., Imafuku, S., Szepietowski, J., Blauvelt, A., Spelman, L., ... & Menter, A. (2022). Pos1046 deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the Phase 3 POETYK PSO program. https://doi.org/10.1136/annrheumdis-2022-eular.2445
Warren , R., Armstrong , A., Gooderham, M., Strober , B., Thaci, D., Imafuku, S., Sofen, H., Spelman, L., Korman, N., Zheng, M., Colston, E., Throup , J., Kundu, S., Kisa, R., Banerjee, S., & Blauvelt, A. (2022). Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials [Poster]. SKIN The Journal of Cutaneous Medicine, 6(2), s4. https://doi.org/10.25251/skin.6.supp.4
2021
Foley, P., Spelman, L., et al. (2021, April). Efficacy and safety of Tildrakizumab in Australian patients with chronic plaque psoriasis in a phase 3 clinical trial [Poster]. In AUSTRALASIAN JOURNAL OF DERMATOLOGY (Vol. 62, pp. 56-56).
Blauvelt, A., Wollenberg, A., Pink, A., Worm, M., Peris, K., Armstrong, A., Spelman, L., Saeki, H., Lynde, C., Thyssen, J.P., Herranz, P., Barbarot, S., Abildgaard Steffensen, L., Kuznetsova, A., & Simpson, E. (2021). Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2). [Poster] American Academy of Dermatology Association Virtual Meeting Experience (AAD VMX), April 23−25, 2021 & EADV Spring Symposium 2021, Virtual, May 2021.
Darch KM, Spelman LJ. What’s new in alopecia areata? An update on current management options and clinical trials. [Poster] Australasian College of Dermatologists 53rd Annual Scientific Meeting, Virtual, Apr 2021.
Darch KM, Spelman LJ. Is coconut driving our patients nuts? An audit of patch test results for coconut and it's derivatives in an outpatient clinic population, and a review of the literature. [Poster] Australasian College of Dermatologists 53rd Annual Scientific Meeting, Virtual, Apr 2021.
Darch KM, Spelman LJ. Hitting the nail on the head: An update on nail disease in psoriasis and review of evidence for the use of biologic agents for its treatment. [Poster] Australasian College of Dermatologists 53rd Annual Scientific Meeting, Virtual, Apr 2021.
Darch KM, Spelman LJ. It's not always as good as gold. A case of contact allergy to gold alloy dental work in an adult male. [Poster] Australasian College of Dermatologists 53rd Annual Scientific Meeting, Virtual, Apr 2021.
Darch KM, Meiklejohn BD, Spelman LJ. Not so easy on the eyes. A case report and review of the literature regarding eye disease in patients treated with dupilumab (Dupixent), a novel biologic agent targeting the IL-4Ra for moderate-to- severe atopic dermatitis. [Poster] Australasian College of Dermatologists 53rd Annual Scientific Meeting, Virtual, Apr 2021.
Darch KM, Spelman LJ. Secukinumab induced bowel disease: A case report and review of the literature. [Poster] Australasian College of Dermatologists 53rd Annual Scientific Meeting, Virtual, Apr 2021.
Darch KM, Spelman LJ. An interesting presentation of xanthogranuloma in an adult male. [Poster] Australasian College of Dermatologists 53rd Annual Scientific Meeting, Virtual, Apr 2021.
Darch KM, Spelman LJ. Hidradenitis Suppurativa recurrence in a caesarean scar: A case report and review of the literature. [Poster] Australasian College of Dermatologists 53rd Annual Scientific Meeting, Virtual, Apr 2021.
Spelman, L. Warren, R. B. Strober, B. Fernandez-Peñas, P. Peterson, L. Cioffi, C. Madden, C. and Ohtsuki, M. Bimekizumab Efficacy Across Subgroups Of Patients With Moderate To Severe Plaque Psoriasis: Pooled Results From Three Multicentre, Randomised, Double‐blinded Phase 3 Trials. [Abstract]. Presented at the International Congress of Dermatology 2021 (10th–13th November)
Sinclair, R. Fernandez-Peñas, P. Murrell, D. F. Foley, P. Freeman, M. Su, J.C. Eisman, S. Rubel, D. Spelman, L. Tan, F.H. and Surian, C. Abrocitinib For Moderate-to-severe Atopic Dermatitis In Australian Patients: A Post Hoc Analysis Of Jade Clinical Trials. [Abstract] International Society of Dermatology - 13th International Congress of Dermatology (Nov 10, 2021).
2020
Wang, J., White, J., Sansone, K., Spelman, L., Sinclair, R., Yang, S., Pan, W., Wei, Z., Connect Biopharma, San Diego, CA, USA and Suzhou, China; Veracity Clinical Research Pty Ltd. Woolloongabba, Queensland, Australia; Sinclair Dermatology, East Melbourne, Australia. (2020). A randomized, double-blind, placebo-controlled, multiple ascending dose study of the safety, pharmacokinetics and preliminary efficacy of CBP-201 in adult patients with moderate to severe atopic dermatitis (CBP-201AU002) [Poster] 29th EADV Congress, Vienna, 28th October - 1st November 2020.
Su J. C., Spelman L. J., Eichenfield L. F., Stein Gold L. F., Cha A., Graham D., Takiya L., Werth J. L., Zang C., Vlahos B. Efficacy and Safety of Crisaborole in Patients ≥3 Months of Age With Mild-to-Moderate Atopic Dermatitis (AD). [Poster] Presented at the Maui Derm Virtual Congress; June 24-27, 2020.
2017
Spelman, L. (2017). AWI002: Trials, tribulations and the value of persisting with non-drug related clinical trials – superfine merino wool base layer garments in atopic dermatitis. Presented at 3rd International Conference on Advanced Clinical Research and Clinical Trials, September 20-21, 2017 Dublin, Ireland. Abstract Link.
Spelman, L. (2017). Assessing safety and tolerability of Volumetric-Modulated Arc Therapy (VMAT) or RapidArc radiation therapy for the treatment of skin cancers and inflammatory skin conditions. Presented at 17th World Dermatology Congress, September 25-26, 2017 Dubai, UAE. Abstract Link.
2014
Langley R, Reich K, Griffiths C, Puig L, Spelman L, Rivas Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis C; for the FIXTURE Study Group. Secukinumab compared with placebo and etanercept in moderate-to-severe plaque psoriasis: a head-to-head comparison of 2 biologics in FIXTURE phase 3 study. [Poster] Society of Dermatology Physician Assistants Annual Summer Dermatology Conference, Indianapolis, Indiana, USA, May-Jun 2014.
Spelman L, Holland T, Davidson K. Best Practice Guidelines for Daylight Photodynamic Therapy (DL-PDT). [Poster] The Australian Dermatology Nurses Association 13th National Conference, Melbourne, Victoria, May 2014.
Langley R, Reich K, Griffiths C, Puig L, Spelman L, Rivas Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis. Secukinumab compared with placebo and etanercept: a head-to-head comparison of 2 biologics in a phase 3 study of moderate-to-severe plaque psoriasis (FIXTURE). [Poster] 10th Annual Maui Derm Conference, Maui, Hawaii, Jan 2014
Langley R, Reich K, Griffiths C, Puig L, Spelman L, Rivas Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis. Secukinumab compared with placebo and etanercept: a head-to-head comparison of 2 biologics in a phase 3 study of moderate-to-severe plaque psoriasis (FIXTURE). [Poster] 2014 Winter Clinical Dermatology Conference, Kona Coast, Hawaii, Jan 2014.
2013
Stein-Gold L, Spelman L, Spellman MC, Hughes M, Zane LT. Safety and efficacy of AN2728 topical ointment, 2% and 0.5%, in a phase 2 dose-ranging study of adolescents with mild-to-moderate atopic dermatitis. [Poster] 2013 Australasian College of Dermatologists Biennial Spring Meeting, Cairns, Queensland, Oct 2013.
Langley R, Reich K, Griffiths C, Puig L, Spelman L, Rivas Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis C. Secukinumab compared with placebo and etanercept: The first 52-week head-to-head comparison of two biologics in a randomized, double-blind phase 3 study in subjects with moderate-to-severe psoriasis (FIXTURE). [Abstract] 22nd Congress of the EADV, Istanbul, Turkey, Oct 2013.
Spelman, L. Daylight PDT: a convenient, similarly effective, and nearly painless alternative to conventional PDT. [Oral Presentation] Dermatology Update 2013, Montreal, Quebec, Canada
2008
Freeman M, Oakley A, Siller G, Rosen R, Salmon P, Spelman L, Shumack S, Rubel D, Birchall N, Katsamas J. Study to determine the optimal tolerated regimen of ingenol mebutate (PEP005) gel for actinic keratosis of the face or face and scalp. [Poster P2010] AAD Summer Meeting, Chicago, Illinois, USA, Jul/Aug 2008.
2007
Spelman L. Metvix in AK’s other than face and scalp. [Poster] 7th EURO-PDT Annual Congress, Paris, France, Mar 2007.